Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endothelial outgrowth cells (EOCs) are a specialized subset of endothelial progenitor cells (EPCs) derived from peripheral blood that exhibit high proliferative capacity and the ability to differentiate into mature, functional endothelial cells. Developed as a potential regenerative therapy by the University of Edinburgh, these cells are culture-expanded and, in specific clinical research settings, labeled with 18F-fluorodeoxyglucose (18F-FDG) to facilitate tracking via PET-CT imaging. The primary therapeutic objective is to treat vascular injury, such as that sustained during coronary angiography and stenting, by promoting rapid re-endothelialization and vascular repair at the site of arterial damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on endothelial outgrowth cells.